Telcagepant is primarily used in the treatment of acute migraine attacks. It works by blocking the calcitonin gene-related peptide (CGRP) receptor, which plays a key role in migraine pathophysiology. This mechanism helps alleviate migraine symptoms such as pain, nausea, and sensitivity to light and sound. Unlike traditional migraine treatments, it does not constrict blood vessels, making it a safer option for patients with cardiovascular risk factors. It is administered orally, providing a convenient option for patients needing rapid relief during migraine episodes. However, its use is limited due to potential liver toxicity observed in clinical trials, and it is not approved for long-term or preventive use.